Compugen (CGEN) Income from Continuing Operations (2009 - 2026)
Compugen (CGEN) posted quarterly Income from Continuing Operations of 7659000.0 for Q1 2026, up 7.59% year-over-year from 7119000.0 in Q1 2025, and down 86.5% on a QoQ basis from 56737000.0 in Q4 2025.
Powered by 
Analysis
Compugen (CGEN) Income from Continuing Operations (2009 - 2026) Analysis & Trends
Compugen has reported Income from Continuing Operations for 18 years, with the latest figure at 7659000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 7659000.0, up 7.59% year-over-year; the trailing twelve-month figure through Mar 2026 was 35883000.0 (up 772.34% YoY), and the FY2025 annual result was 35343000.0, up 348.35% from the prior year.
- Income from Continuing Operations eased to 7659000.0 in Q1 2026, from 56737000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 56737000.0 in Q4 2025 and troughed at 28000000.0 in Q2 2023.
- A 5-year average of 1352647.06 and a median of 3092000.0 in 2022 frame the typical range for Income from Continuing Operations.
- The widest annual swing landed in 2023, when Income from Continuing Operations tumbled 198.03%; it then jumped 1027.53% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 3092000.0 in 2022, then jumped by 414.13% to 9713000.0 in 2023, then slumped by 162.98% to 6117000.0 in 2024, then jumped by 1027.53% to 56737000.0 in 2025, then sank by 86.5% to 7659000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 7659000.0 in Q1 2026, 56737000.0 in Q4 2025, and 6899000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Compugen | 241.50 Mn | 155.89 Mn | -92,000.00 | -22.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.31 Mn |
| Mar 31, 2026 | 7.66 Mn |
| Dec 31, 2025 | 56.74 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | -21.61 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | -6.12 Mn |
| Sep 30, 2024 | 10.28 Mn |
| Jun 30, 2024 | -16.62 Mn |
| Mar 31, 2024 | 7.26 Mn |
| Dec 31, 2023 | 9.79 Mn |
| Sep 30, 2023 | -9.85 Mn |
| Jun 30, 2023 | -28.00 Mn |
| Mar 31, 2023 | 9.31 Mn |
| Dec 31, 2022 | -3.03 Mn |
| Sep 30, 2022 | -11.75 Mn |
| Jun 30, 2022 | 28.56 Mn |
| Mar 31, 2022 | -9.71 Mn |
| Dec 31, 2021 | -6.63 Mn |
| Sep 30, 2021 | -8.18 Mn |